Description

BIM-23190 hydrochloride, a somatostatin analog, a selective SSRT2 and SSRT5 agonist, exhibits Ki values of 0.34 nM and 11.1 nM for SSTR2 and SSTR5, respectively. BIM-23190 can be used in the study for cancer and acromegaly[1][3].–80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)–Cancer-programmed cell death–C57H80ClN13O12S2—-[1]I Shimon, et al. Somatostatin receptor (SSTR) subtype-selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas. Novel potential therapy for functional pituitary tumors. J Clin Invest. 1997 Nov 1;100(9):2386-92.|[2]Federica Barbieri, et al. Differential efficacy of SSTR1, -2, and -5 agonists in the inhibition of C6 glioma growth in nude mice. Am J Physiol Endocrinol Metab. 2009 Nov;297(5):E1078-88.|[3]T J Gillespie, et al. Novel somatostatin analogs for the treatment of acromegaly and cancer exhibit improved in vivo stability and distribution. J Pharmacol Exp Ther. 1998 Apr;285(1):95-104.—-1238.91–99.64–O=C([C@@H](CC1=CNC2=CC=CC=C12)NC([C@H](CC3=CC=C(O)C=C3)N4)=O)N[C@@H](CCCCN)C(N[C@@H](CC)C(N[C@H](C(N[C@@H]([C@@H](C)O)C(N)=O)=O)CSSC[C@H](NC([C@@H](CC5=CC=CC=C5)NC(CN6CCN(CCO)CC6)=O)=O)C4=O)=O)=O.Cl–Cancer–DMSO : 100 mg/mL (ultrasonic)|H2O : 100 mg/mL (ultrasonic)–Somatostatin Receptor–SSTR2;SSTR5–GPCR/G Protein;Neuronal Signaling–Peptides